Standard Biotools Inc (LAB)vsMerck & Company Inc (MRK)
LAB
Standard Biotools Inc
$0.73
-1.72%
HEALTHCARE · Cap: $324.80M
MRK
Merck & Company Inc
$128.66
+2.56%
HEALTHCARE · Cap: $283.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 76148% more annual revenue ($65.77B vs $86.25M). LAB leads profitability with a 90.7% profit margin vs 13.6%. MRK earns a higher WallStSmart Score of 50/100 (D+).
LAB
Hold45
out of 100
Grade: D+
MRK
Hold50
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LAB.
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$128.66
$47.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 91 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Areas to Watch
4.6% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -16.8% — below average capital efficiency
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LAB
The strongest argument for LAB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 90.7% and operating margin at -44.5%.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bear Case : LAB
The primary concerns for LAB are Revenue Growth, EPS Growth, Market Cap.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Key Dynamics to Monitor
LAB carries more volatility with a beta of 1.38 — expect wider price swings.
MRK is growing revenue faster at 4.9% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor MEDICAL DEVICES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (50/100 vs 45/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Standard Biotools Inc
HEALTHCARE · MEDICAL DEVICES · USA
Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?